Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China

Overview of attention for article published in Frontiers in Pharmacology, November 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 8 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,739 followers.

New Research: Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China https://t.co/5EhKNjIwrX #pharmacology

18 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.